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Liver cirrhosis is the end stage of various chronic 
liver diseases which is known to have high prevalence 
and low survival rate. It’s affected about 2.8 million 
people worldwide with mortality of 1.3 million 
death in 2015.1 Multiple repeated injuries such as 
metabolic dysfunction, alcohol abuse, viral hepatitis, 
and autoimmune diseases progressively lead to liver 
fibrosis and eventually liver cirrhosis. The degree 
of liver fibrosis is not only important for patient’s 
prognosis, but also a critical aspect for chronic liver 
disease treatment and management. Therefore, liver 
fibrosis diagnosis is mandatory for every chronic liver 
disease.
As the disease burden grows, the need for liver 
fibrosis diagnosis also increases. For chronic hepatitis 
B virus (HBV) infection alone, more than 5 million 
patients in Indonesia will require liver fibrosis 
assessment in 2020. As the gold standard, invasive 
procedure of liver biopsy alone is not practical since 
it is associated with various complications including 
hospitalization in 1-5% of cases and mortality in 
0.01-0.1% of cases as well as poor patient adherence 
for repeated biopsies.2 Therefore various non-invasive 
approaches such as scoring systems using several 
serum biomarkers and imaging technology have been 
investigated intensively. 
Transient elastography (TE) is one of the non-
invasive methods for diagnosing liver fibrosis. It 
uses a low frequency vibration transmitted through 
the right lobe of the liver.3 Recent systematic review 
and meta-analysis by Geng et al, showed that TE 
has high sensitivity and specificity of 81% and 88% 
respectively for detecting liver fibrosis with area under 
the receiver operating characteristic (AUROC) curve 
of 0.931.4 However, TE is only available in larger 
hospital and not evenly distributed across region in 
Indonesia. Therefore, several, more affordable and 
widely available, serum biomarkers have been studied 
for diagnosing liver fibrosis.
Red cell distribution width (RDW) to platelet 
ratio (RPR) is one of the non-invasive serum 
biomarkers that has been investigated recently for 
diagnosing liver fibrosis. It was known that RDW 
was positively correlated with liver fibrosis and 
cirrhosis whereas platelet and haemoglobin were 
negatively correlated with fibrosis and cirrhosis.5 
Chen et al in 2013 demonstrated RPR had high area 
under receiver operating characteristic/ROC curve 
(AUCs) for predicting liver fibrosis and cirrhosis in 
chronic hepatitis B (CHB) patients with 0.825 and 
0.884 respectively.5 More recent study in Indonesia 
by Tubung et al showed that RPR using cut off of 
0.0666 also had high AUC of 0.816 with sensitivity 
and specificity of 76.9% and 78.6% respectively 
for predicting severe liver fibrosis in CHB patients. 
RPR was not inferior to aspartate aminotransferase to 
platelet ratio index (APRI) which is also a liver fibrosis 
serum biomarker for predicting sever liver fibrosis in 
CHB patients.6
Although RPR is not the only serum biomarker 
for liver fibrosis diagnostic, other biomarkers such 
as FibroTest, Fibroindex, aspartate aminotransferase 
(AST)/alanine aminotransferase (ALT) ratio, APRI 
and FIB-4 were mostly used in hepatitis C virus (HCV) 
infection patients that might produce conflicting result 
for predicting patients with HBV infection.6 Therefore 
RPR is a promising, more affordable and widely 
available, non-invasive biomarker for diagnosing liver 
fibrosis particularly in Indonesia where HBV infection 
is dominant.
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